PSMD4 and malignant colon neoplasm: We provide evidence from cell and animal models in support of this hypothesis and suggest that targeting PSMD4 by the new-generation proteasomal inhibitor carfilzomib may be more effective at overcoming 5-FU resistance and suppressing the tumor burden in nude mice induced by cNrf2-overexpressing colon cancer cells.